Difference between revisions of "Renal cell carcinoma, VHL-associated"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "'''contains dosing details in manuscript'''" to "'''dosing details in manuscript have been reviewed'''") |
Warner-admin (talk | contribs) m (Text replacement - "'''dosing details in manuscript have been reviewed'''" to "'''dosing details in manuscript have been reviewed by our editors'''") |
||
Line 39: | Line 39: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''MK-6482-004:''' Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R; MK-6482-004 Investigators. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 Nov 25;385(22):2036-2046. [https://doi.org/10.1056/nejmoa2103425 link to original article] '''dosing details in manuscript have been reviewed''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9275515/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/34818478/ PubMed] [https://clinicaltrials.gov/study/NCT03401788 NCT03401788] | + | # '''MK-6482-004:''' Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R; MK-6482-004 Investigators. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 Nov 25;385(22):2036-2046. [https://doi.org/10.1056/nejmoa2103425 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9275515/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/34818478/ PubMed] [https://clinicaltrials.gov/study/NCT03401788 NCT03401788] |
[[Category:Renal cell carcinoma regimens]] | [[Category:Renal cell carcinoma regimens]] | ||
[[Category:Biomarker-specific pages]] | [[Category:Biomarker-specific pages]] | ||
[[Category:Renal cell carcinomas]] | [[Category:Renal cell carcinomas]] |
Latest revision as of 12:20, 15 July 2024
Page editor | Section editor | ||
---|---|---|---|
Teja Ganta, MD Icahn School of Medicine at Mount Sinai New York, NY, USA |
Ali Raza Khaki, MD Stanford University Palo Alto, CA, USA |
Note: these are regimens tested in populations with a diagnosis of Von Hippel Lindau (VHL) Disease-associated renal cell carcinoma, please see the main RCC page for other regimens.
1 regimens on this page
1 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
NCCN
- NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Kidney Cancer.
All lines of therapy
Belzutifan monotherapy
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Jonasch et al. 2021 (MK-6482-004) | 2018-05-31 to 2019-03-29 | Phase 2 (RT) |
References
- MK-6482-004: Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R; MK-6482-004 Investigators. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 Nov 25;385(22):2036-2046. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT03401788